Welcome to our dedicated page for Rocket Pharmaceuticals news (Ticker: RCKT), a resource for investors and traders seeking the latest updates and insights on Rocket Pharmaceuticals stock.
Rocket Pharmaceuticals, Inc. reports developments in rare-disease genetic medicines, including its commercial-stage therapy KRESLADI for pediatric patients with severe leukocyte adhesion deficiency-I and its broader pipeline of investigational gene therapies. Company updates commonly address FDA actions, clinical-program progress, regulatory submissions, and financial results tied to research, development, and commercial readiness.
Recurring news themes include the AAV cardiovascular portfolio, such as RP-A501 for Danon disease, RP-A601 for PKP2-arrhythmogenic cardiomyopathy, and RP-A701 for BAG3-related dilated cardiomyopathy. Rocket also reports capital and balance-sheet actions, including monetization of its Rare Pediatric Disease Priority Review Voucher, as well as presentations at healthcare conferences.
Rocket Pharmaceuticals (NASDAQ: RCKT) has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for RP-A601, its gene therapy treatment for PKP2-arrhythmogenic cardiomyopathy (ACM). This marks the company's fifth RMAT designation.
The designation was granted based on positive Phase 1 clinical trial results where all three adult patients treated with RP-A601 showed increased PKP2 protein expression, with two patients experiencing increases of 110% and 398%. Patients demonstrated improved desmosomal integrity and clinical benefits including enhanced right ventricular function and quality of life, with KCCQ-12 scores increasing by 34-41 points.
The RMAT designation provides benefits including intensive FDA guidance, expedited review, and potential accelerated approval pathways for this treatment of life-threatening heart failure disease.
Rocket Pharmaceuticals (NASDAQ: RCKT) has received FDA clearance for its Investigational New Drug (IND) application for RP-A701, a novel gene therapy candidate targeting BAG3-associated Dilated Cardiomyopathy (BAG3-DCM). This marks the company's third clinical-stage gene therapy candidate in its AAV cardiovascular portfolio.
The upcoming Phase 1 clinical trial will be a multi-center, dose-escalation study evaluating RP-A701's safety, biological activity, and preliminary efficacy in adult patients with BAG3-DCM. The trial will focus on adults with implantable cardioverter defibrillators (ICDs) and advanced disease who are at high risk for heart failure progression and cardiac death.
BAG3-DCM is characterized as a rare, inherited heart condition caused by BAG3 gene mutations, resulting in early-onset, progressive heart failure with high morbidity and premature mortality. The study will assess BAG3 protein expression, changes in cardiac biomarkers, and clinical predictors of disease progression.
- Well-tolerated safety profile with no dose-limiting toxicities - Increased PKP2 protein expression (110% and 398% improvements in two patients) - Enhanced protein expression and desmosomal localization of key proteins - Improved/stabilized heart function and reduced arrhythmia burden - Quality of life improvements with KCCQ-12 score increases of 34-41 points - PVC reductions of 9% to 63% from baseline - Improved NYHA class from Class II to Class I in patients followed beyond six months
This marks Rocket's second successful gene therapy from their AAV cardiovascular portfolio, advancing their mission to develop curative treatments for rare heart conditions.Rocket Pharmaceuticals (NASDAQ: RCKT) reported its Q1 2025 financial results and pipeline updates. The company ended Q1 with $318.2 million in cash and investments, providing runway into Q4 2026. Key pipeline developments include ongoing Phase 2 pivotal study of RP-A501 for Danon disease with updates expected mid-2025, anticipated initial Phase 1 data for RP-A601 in PKP2-ACM in May 2025, and planned IND submission for BAG3-DCM program mid-2025.
Financial highlights show R&D expenses decreased to $35.9 million from $45.2 million year-over-year, while G&A expenses increased to $28.4 million from $22.1 million. Net loss was $61.3 million ($0.56 per share). The company appointed Sarbani Chaudhuri as Chief Commercial & Medical Affairs Officer and continues regulatory progression for RP-L102 and KRESLADITM programs.
Rocket Pharmaceuticals (NASDAQ: RCKT), a late-stage biotechnology company focused on genetic therapies for rare disorders, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's CEO, Gaurav Shah, M.D., will engage in a fireside chat scheduled for 8:45 a.m. ET on Tuesday, April 8, 2025. The presentation will be accessible via webcast on the company's Investors section website, with replay availability for approximately 30 days after the event.
Rocket Pharmaceuticals (NASDAQ: RCKT) reported its Q4 and full-year 2024 financial results, highlighting significant progress in its gene therapy pipeline. The company's cash position stands at $372.3 million, providing runway into Q3 2026.
Key developments include ongoing dosing in the Phase 2 pivotal study of RP-A501 for Danon disease, with program updates expected in H1 2025. Long-term data from the Phase 1 study showed sustained efficacy up to five years. The company completed enrollment in the low-dose cohort of RP-A601 for PKP2-ACM, with initial data expected in H1 2025.
Financial results show R&D expenses decreased to $171.2 million from $186.3 million in 2023, while G&A expenses increased to $102.0 million from $73.3 million. Net loss was $258.7 million ($2.73 per share) compared to $245.6 million ($2.92 per share) in 2023. The company raised $182.5 million through a public offering in December 2024.
Rocket Pharmaceuticals (NASDAQ: RCKT), a late-stage biotechnology company focused on genetic therapies for rare disorders, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Gaurav Shah, M.D., the company's CEO, will deliver a presentation on Monday, January 13, at 3:45 p.m. PT and will be available for investor meetings throughout the conference.
The presentation will be accessible via webcast and will be made available on the company's website in the Investors section. Rocket Pharmaceuticals specializes in developing sustainable pipeline solutions for rare disorders with high unmet medical needs.
Rocket Pharmaceuticals (NASDAQ: RCKT) has announced the pricing of an upsized public offering of 13,200,000 shares of common stock at $12.50 per share. The offering is expected to generate gross proceeds of $165 million before deducting underwriting costs and expenses. The company has granted underwriters a 30-day option to purchase up to an additional 1,980,000 shares. The offering is anticipated to close around December 12, 2024. Morgan Stanley, Leerink Partners, and Cantor are serving as joint book-running managers, with LifeSci Capital acting as lead manager.